ARTICLE

CLINICAL QUESTION
What is the efficacy and safety of BI 1015550, an oral preferential inhibitor of PDE4B subtype, in patients with IPF?

SUMMARY
Idiopathic pulmonary fibrosis is a progressive interstitial lung disease with high mortality. There are currently two FDA approved antifibrotic drugs available that slow, but not stop, progression of fibrotic lung disease. Phosphodiesterase 4 (PDE4) inhibition is associated with anti-inflammatory and antifibrotic properties. Thus, preferential inhibition of the PDE4B subtype may be beneficial in the treatment of IPF.

This study is a phase 2, double-blind, placebo-controlled trial conducted to investigate the safety and efficacy of BI 1015550, an oral inhibitor of the PDE4B subtype in patients with IPF. 147 patients were randomly assigned in a 2:1 ratio to receive BI 1015550 at a dose of 18mg twice daily or placebo. The primary end point was the change from baseline in the forced vital capacity (FVC) at 12 weeks. Data was analyzed with a Bayesian approach separately according to background use or nonuse of antifibrotic therapy.

For patients with IPF, treatment with BI 101550 prevented a decrease in lung function over 12 weeks. The sample size was small and the results need to be confirmed in a larger trial. The safety profile of BI 101550 warrants further research in a phase III trial.

On behalf of the National Jewish Health ILD Program Providers:
Matthew Koslow, MD
Evans Fernandez, MD, MS
Tristan J. Huie, MD
Rebecca Keith, MD
Michael P. Mohning, MD
Katherine Rosen, NP
Joshua J. Solomon, MD
Zulma X. Yunt, MD